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Abstract
Interleukin-6 (IL-6) is involved in lung cancer tumorigenesis, tumor progression, metastasis, and drug resistance.
Previous studies show that blockade of IL-6 signaling can inhibit tumor growth and increase drug sensitivity in mouse
models. Clinical trials in non-small cell lung cancer (NSCLC) reveal that IL-6 targeted therapy relieves NSCLC-
related anemia and cachexia, although other clinical effects require further study. We crossed IL-6-/- mice with
KrasG12D mutant mice, which develop lung tumors after activation of mutant KrasG12D, to investigate whether IL-6
inhibition contributes to tumor progression and survival time in vivo. KrasG12D; IL-6-/- mice exhibited increased
tumorigenesis, but slower tumor growth and longer survival, than KrasG12D mice. Further, in order to investigate
whether IL-6 deletion contributes to suppression of lung cancer metastasis, we generated KrasG12D; p53flox/flox; IL-6-/-
mice, which developed lung cancer with a trend for reduced metastases and longer survival than KrasG12D; p53flox/flox
mice. Tumors from KrasG12D; IL-6-/- mice showed increased expression of TNFα and decreased expression of
CCL-19, CCL-20 and phosphorylated STAT3 (pSTAT3) than KrasG12D mice; however, these changes were not
present between tumors from KrasG12D; p53flox/flox; IL-6-/- and KrasG12D; p53flox/flox mice. Upregulation of pSTAT3 and
phosphorylated AKT (pAKT) were observed in KrasG12D tumors with p53 deletion. Taken together, these results
indicate that IL-6 deletion accelerates tumorigenesis but delays tumor progression and prolongs survival time in a
Kras-driven mouse model of lung cancer. However, these effects can be attenuated by p53 deletion.
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Introduction
Accumulating evidence indicates that inflammation
contributes to tumorigenesis, tumor progression, and
metastasis [1,2]. Oncogene-associated inflammation leads to
production of inflammatory cytokines such as interleukin-6
(IL-6) [3,4], a pleiotropic cytokine involved in inflammation,
immunity, bone metabolism, neural development, reproduction,
and hematopoiesis [5]. However, IL-6 is also associated with
increased risk of lung cancer [6-8]. IL-6 can be detected in
breath condensate of patients with non-small cell lung cancer
(NSCLC) [9], and in serum of some lung cancer patients, but is
not detectable in patients with benign lung disease [10].
Elevated IL-6 levels contribute to malignant pleural effusion
[11,12], postoperative complications [13], and postoperative
recurrence [14] of lung cancer. Several studies have correlated
high circulating IL-6 levels with poor survival of lung cancer
patients [15-23]. IL-6-mediated inflammation correlates with
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debilitating cancer-related symptoms such as fatigue,
thromboembolism, cachexia, and anemia [3], and IL-6 signaling
activation correlates with lung cancer chemotherapy resistance
[16,24]. These studies suggest an important role for IL-6 in
several aspects of lung cancer.
IL-6 expression can be detected in lung tumors [25] and in
53% of lung cancer cell lines [26], and IL-6 pathways are
activated in a human lung cancer stem cell line [27-29].
Functional assays suggest that IL-6 influences the ability of
cancer cells to metastasize to distant sites [30,31] and that IL-6
promotes tumor growth in a paracrine fashion in vivo [4,26,32].
Therefore, it is perhaps not surprising that IL-6 knockdown,
genetic ablation, or treatment with a neutralizing IL-6 antibody
inhibits tumor growth in vivo [4,33]. Conversely, activation of
IL-6 signaling contributes to resistance to epidermal growth
factor receptor (EGFR) inhibitors in a mouse model of NSCLC
[34,35], while blockade increases drug sensitivity in xenograft
models [34].
An IL-6 monoclonal antibody therapy would be predicted to
inhibit the inflammatory microenvironment in lung cancer. One
such therapy, ALD518, has undergone preclinical and Phase I
and II clinical trials. It appears to be well tolerated and
ameliorates NSCLC-related anemia and cachexia [3], although
the totality of clinical outcomes needs further study.
To assess the contribution of IL-6 signaling inhibition on
tumor progression and survival time in vivo, we crossed IL-6-/-
mice with mutant KrasG12D mice because IL-6 is a downstream
effector of oncogenic Ras to promote tumorigenesis[4]. NSCLC
is often diagnosed with metastasis and has a poor prognosis.
The treatment and prevention of lung cancer metastases are
major unmet needs [36]. Inactivating mutations in p53 are
found in at least 50% of NSCLC cases [36], and KrasG12D
activation accompanied by p53 deletion can cause lung tumor
metastasis [37]. To study the function of IL-6 in metastasis, we
also generated KrasG12D; p53flox/flox; IL-6-/- mice..
Materials and Methods
Mice
IL-6-/- mice were purchased from The Jackson Laboratory
and maintained in sterile housing [38]. Conditional Lox–Stop–
Lox KrasG12D (hereafter referred to as KrasG12D) mice [39] and
p53flox/flox mice [40] were described previously. KrasG12D and
KrasG12D; lL-6-/- mice were inoculated with 5 × 106 PFU of
adenoviral Cre (adeno-Cre) by intranasal inhalation to activate
oncogenic KrasG12D in the lungs. KrasG12D; p53flox/flox and
KrasG12D; p53flox/flox;IL-6-/- mice were inoculated with 5 × 105 PFU
of adeno-Cre. All experimental procedures were performed in
accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. The protocol was
approved by the Institutional Animal Care and Use Committee
at Dana-Farber Cancer Institute (permit number 04-094). All
surgeries were performed under Avertin anesthesia to minimize
suffering. After euthanasia, organs, including heart, liver,
spleen, kidney, stomach, intestine, spine, brain, breast, skin,
and testis or ovary, were undergone gross inspection for
metastases. Lung tumors adhered to the pleura were
considered parietal pleural metastases. Suspected metastases
were harvested and confirmed by histological features.
Histology and immunohistochemistry
After euthanasia, the lungs were removed and fixed in 10%
neutral buffered formalin overnight before embedding in
paraffin. Five-micrometer sections of mouse lung tissues were
cut. Some sections were stained with H&E. For
immunohistochemistry, heat treatment with citrate solution
(Beijing ZhongShan Golden Bridge Biotechnology Co., China)
in a decloaking chamber (Biocare Medical) unmasked antigens
for phosphorylated ERK (pERK), BrdU, Ki67, Endomucin and
Caspase-3 staining. Whole lung tissue sections were incubated
overnight at 4°C with primary antibodies: pERK (4370, Cell
Signaling) at 1:100; BrdU (ab6326, Abcam) at 1:200; Ki67
(ab15580, Abcam) at 1:200; Endomucin (14-5851,
eBioscience) at 1:100; cleaved Caspase-3 (9661, Cell
Signaling) at 1:300. Digest-All 2B Trypsin (Invitrogen) was used
to retrieve the antigen for MAC2 (CL8942AP, Cedarlane)
staining at 1:5000. At 400X magnification, all MAC2-positive
macrophages in tumors were counted within 3 microscope
fields with the most MAC2-positive macrophages after review
of the whole lung section. Three mice per genotype were
analyzed.
Proliferation analysis
At 20 weeks post-infection, mice were injected
intraperitoneally with 10 μL of 10 mM BrdU in PBS per gram of
body weight and euthanized after 2 hours. Whole lungs were
harvested and processed as described above. At 400X
magnification, all BrdU-positive tumor cell nuclei were counted
within 3 microscope fields with the most BrdU-positive nuclei
after review of the whole lung section. Four mice per genotype
were analyzed. Same method was used to calculate Ki67-
labeled tumor cells on sections from mice 28 weeks post-
infection with adeno-Cre.
Western blotting
Lung tumors were harvested from KrasG12D and KrasG12D;
lL-6-/- mice 32 weeks post-infection and from KrasG12D; p53flox/flox
and KrasG12D; p53flox/flox; IL-6-/- mice 15 weeks post-infection for
Western blot analysis. Tumors were lysed with a homogenizer
in RIPA buffer (50 mM Tris pH 7.4, 150 mM sodium chloride,
1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM EDTA)
containing complete mini protease inhibitors (Roche) and
phosphatase inhibitors (5870, Cell Signaling). Nuclear and
Cytoplasmic Extraction Kit (CW199B, CoWin Biotech Co.,
Ltd. China) was used to extract cytoplasmic (C) and nuclear
(N) fractions from tumors. Lysates (20 μg per lane) were
separated on 10% polyacrylamide gels, transferred to PVDF
filters, and incubated overnight at 4°C with antibodies to β-actin
(sc-1615, Santa Cruz), pERK (4376, Cell Signaling), total-ERK
(9102, Cell Signaling), pAKT (4060, Cell Signaling), total-AKT
(4685, Cell Signaling), pSTAT3 (9145, Cell Signaling), STAT3
(sc-7179, Santa Cruz), p65 (sc-372, Santa Cruz), PARP (9532,
Cell Signaling), GAPDH (TA-8, Beijing ZhongShan Golden
Bridge Biotechnology Co., China), or β-catenin (ab32572,
p53 Loss Attenuates effects of IL-6 Inhibition
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Abcam). Western blots were exposed to X-ray films or scanned
with an ImageQuant LAS 4000mini (GE healthcare).
Quantitative real-time PCR
mRNA was extracted from tumors of KrasG12D and KrasG12D;
lL-6-/- mice 32 weeks post-infection and KrasG12D; p53flox/flox and
KrasG12D; p53flox/flox; IL-6-/- mice around 16 weeks post-infection
for analysis. 2μg total RNA was reverse transcribed to cDNA
using SuperRT cDNA synthesis kit (Beijing CoWin Biosciences
Co., Ltd. China). Real-time PCR was performed using the
BioRad iQ5 Realtime PCR system and StepOnePlus Realtime
PCR system (ABI) with Realtime PCR Master Mix containing
SYBR Green (QPK-201 ,TOYOBO, Japan) and unique primers
(Table S1). Three to four samples for each group were
detected.Gene expression results were normalized to β-actin
mRNA.
Statistical analysis
The Student’s t-test was used to evaluate lesion number and
number of BrdU or Ki67- positive cells. Fisher’s exact test
evaluated metastatic rate. Kaplan–Meier analysis evaluated
survival time. Expression differences among four groups were
analyzed by ANOVA.  P<0.05 was considered statistically
significant.
Results
IL-6 deletion accelerates oncogenic KrasG12D-induced
lung tumorigenesis
As previously described, KrasG12D mice developed lung
tumors following a long latency [39]. IL-6-/- mice developed
normally [38], and did not show lung tumors through 54 weeks
of age (data not shown). Following adeno-Cre inhalation, PCR
analysis confirmed recombination of the conditional KrasG12D
allele (Figure S1). KrasG12D; IL-6-/- mice had a median survival
of 37 weeks after adeno-Cre inoculation, significantly longer
than KrasG12D mice (P<0.0001) (Table 1). Mice were euthanized
at 2, 4, 20, 28, and 32 weeks post-infection, and lung lesions in
H&E-stained sections were analyzed at each time point. At 2
weeks post-infection (n = 3), both KrasG12D and KrasG12D; IL-6-/-
mice had early lung lesions. At 4 weeks post-infection,
KrasG12D; IL-6-/- mice had more early lung lesions than KrasG12D
mice (Figure 1A-C). These lesions were atypical adenomatous
hyperplasia (AAH) and epithelial hyperplasia (EH) of the
bronchioles, as reported previously [39].
IL-6 deletion retards oncogenic KrasG12D-induced lung
tumor progression
At 20 weeks post-infection, lung tumors in KrasG12D; IL-6-/-
mice were modestly smaller and less dense than those in
KrasG12D mice (Figure 1D and E). At 28 weeks post-infection, in
comparison with KrasG12D mice, more lesions were observed in
KrasG12D; IL-6-/- mice with the majority of lesions in early stages
of tumor development (Figure 1F). However, tumors 3-10 mm
in diameter were observed in lungs of KrasG12D mice, while the
majority of KrasG12D; IL-6-/- lung tumors were less than 1.5 mm
(Figure 1G-I). Further, although IL-6 signaling promotes skin
tumor growth and angiogenesis in a paracrine fashion [4], we
did not detect any difference between KrasG12D and KrasG12D;
IL-6-/- mice after immunohistochemical staining with
Endomucin, a microvessel density marker to measure
angiogenesis index (Figure 1J and K).
IL-6 deletion attenuates lung tumor proliferation
To determine whether tumor proliferation is affected by IL-6
deletion in vivo, we measured BrdU-labeling cells in lung
tumors. Significantly fewer labeled nuclei were observed in
lung sections from KrasG12D; IL-6-/- mice 20 weeks post-infection
with adeno-Cre compared with those derived from control
KrasG12D mice (Figure 2A-C). Similar results were observed
from Ki67 staining in lung sections from KrasG12D and KrasG12D;
IL-6-/- mice 28 weeks post-infection with adeno-Cre (Figure S2).
Expression of pERK, which acts downstream of Kras and is
associated with cancer cell proliferation, was reduced in tumors
from KrasG12D; IL-6-/- mice 20 weeks post-infection with adeno-
Cre compared to KrasG12D mice (Figure 2D and E). Caspase-3
staining revealed no differences in tumor cell apoptosis
between KrasG12D and KrasG12D; IL-6-/- mice (Figure 2F and G).
IL-6 deletion extends survival of KrasG12D; p53flox/flox mice
As previously reported, no metastases or local invasions
were detected in KrasG12D mice [39], and similar results were
observed in KrasG12D; IL-6-/- mice. KrasG12D activation
accompanied by p53 deletion can cause lung tumor metastasis
[37], therefore, KrasG12D; p53flox/flox; IL-6-/- mice were generated
to investigate the influence of IL-6 deletion on lung cancer
metastasis.
p53 allelic recombination was confirmed by PCR (Figure S3).
IL-6 deletion increased median survival of KrasG12D; p53flox/flox
mice (P<0.01) (Table 1) despite substantial lung tumor burden
in both KrasG12D; p53flox/flox and KrasG12D; p53flox/flox; IL-6-/- mice 12
weeks post-infection (Figure 3A and B). BrdU staining indicated
both groups of lung tumors were highly proliferative (Figure 3C
and D), and pERK expression was high in both groups (Figure
3E and F); no statistical differences were observed.
Table 1. Comparison of lung cancer cohorts.
Genotype
Number
treated
Median survival
(weeks)*
Survival range
(weeks)
IL-6-/- 13 >54  
KrasG12D 14 34.6 27.9 ~ 39.0
KrasG12D; IL-6-/- 38 37.0a 29.3 ~ 46.7
p53flox/flox 8 >52  
p53flox/flox; IL-6-/- 9 >52  
KrasG12D; p53flox/flox 43 16.3 11.1 ~ 19.7
KrasG12D; p53flox/flox;
IL-6-/- 44 17.4
b 12.7 ~ 23.4
a KrasG12D; IL-6-/- mice had significantly longer survival than KrasG12D mice
(P<0.0001). b KrasG12D; p53flox/flox; IL-6-/- mice had significantly longer survival
than KrasG12D; p53flox/flox mice (P<0.01). * Median latency shown is after adeno-
Cre treatment at 6-10 weeks of age, estimated by Kaplan–Meier analysis.
doi: 10.1371/journal.pone.0080885.t001
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For comparison, 17 KrasG12D; p53flox/flox; IL-6-/- mice and 19
KrasG12D; p53flox/flox mice were analyzed for metastases around
16 weeks post-infection with adeno-Cre (Table 2).
Histologically, metastases were found in 5 of 17 KrasG12D;
p53flox/flox; IL-6-/- mice (29.4%) and 10 of 19 KrasG12D; p53flox/flox
mice (52.6%), although this difference was not significant
(P=0.19). Metastatic lesions to the parietal pleura, thymus
(Figure S4A and B), and lymph nodes were observed in both
KrasG12D; p53flox/flox and KrasG12D; p53flox/flox; IL-6-/- mice (Figure
3G and H). Heart metastases (Figure S4C) were observed in 2
of 19 KrasG12D; p53flox/flox mice (Table 2).
IL-6 deletion alters, but p53 deletion attenuates, some
inflammatory cytokines
To investigate whether IL-6 deletion affected inflammation,
we measured macrophage density using MAC2 staining [41].
No significant changes in macrophage number were observed
among tumors from KrasG12D, KrasG12D; IL-6-/-, KrasG12D; p53flox/
flox, and KrasG12D; p53flox/flox; IL-6-/- mice (Figure 4A-E). We also
measured no change in CD3 expression, a T cell marker, in
any of the four tumor groups (Figure S5B).
Several cytokines play important roles in the inflammatory
process. The list includes IL-1, TNFα, and IL-6. Chemokines
represent the largest family of cytokines and are classified into
polypeptide groups by the location of cysteine residues near
the amino terminus (e.g., C-C, C-X-C, or CX3C) [42].
Figure 1.  IL-6 deletion promotes tumorigenesis but retards tumor progression of KrasG12D-driven lung cancer.  (A and B)
Representative images of H&E-stained lung tissue sections from (A) K and (B) KI mice 4 weeks post-infection with adeno-Cre.
Arrows indicate early lesions. (C) Quantification of lesions in K (n=3) and KI (n=5) mice 4 weeks post-infection with adeno-Cre. Data
are shown as mean + s.e.m. **P<0.01. (D and E) Representative images of H&E-stained lung tissue sections from (D) K and (E) KI
mice 20 weeks post-infection with adeno-Cre. (F) Quantification of small lesions (<1.5 mm) in K and KI mice (n=6) 28 weeks post-
infection with adeno-Cre. Data shown are mean + s.e.m. *P<0.05. (G and H) Representative images of H&E-stained lung tissue
sections from (G) K and (H) KI mice28 weeks post-infection with adeno-Cre. Arrow indicates a large tumor. (I) Quantification of large
tumors (>1.5 mm) in K and KI mice (n=6) 28 weeks post-infection with adeno-Cre. Data shown are mean + s.e.m. **P<0.01. (J and
K) Representative images of Endomucin-stained lung tissue sections from (J) K and (K) KI mice 28 weeks post-infection with
adeno-Cre. Scale bar indicates 500 μm in (A, B, D, E, G and H), or 100 μm in (J and K). Abbreviations: K=KrasG12D. KI=KrasG12D;
IL-6-/-.
doi: 10.1371/journal.pone.0080885.g001
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Oncogenic Ras induces the secretion of the ELR1 + CXC
chemokine family to promote tumorigenesis [43]. Some
chemokines and growth factors are involved in tumor
progression [42], so we screened inflammatory cytokine
changes in tumors with real-time PCR. Three samples each
tumor group were used to perform real-time PCR without
replicate. There were no significant differences found for IL-1α,
CXCL-1, CXCL-5, CXCL-9, CXCL-12, CXCL-16, TGF-β2,
BMP2, BMP4, CCL-2, CCL-7, CCL-8, CCL-9, CCL-22, CCL-28
and CX3CL-1 expression among four groups of tumors (Figure
S5). The screening results showed some changing trends in
some inflammatory cytokines (Figure S5). We confirmed the
changes using triplicate real-time PCR reactions with 3 to 4
samples in each group. Elevated expression of TNFα and
reduced expression of CCL-19 and CCL-20 were detected in
tumors from KrasG12D; IL-6-/- mice compared to KrasG12D mice.
However, these changes were absent between tumors from
KrasG12D; p53flox/flox and KrasG12D; p53flox/flox; IL-6-/- mice. While no
statistical differences in IL-1β, CCL-7, CCL-8, CCL-24 and
CXCL-5 gene expression were confirmed among four tumor
groups (Figure 4F and G).
We also examined the nuclear localization of NF-κB subunit
p65, which is important in cancer-related inflammation and
malignant progression [44,45]. However, no significant
localization change was observed among tumors from the four
genotypes (Figure S6). And no dramatic change was observed
in β-catenin expression in nucleus (Figure S6), which is related
to lung cancer development [46]. Expression of pSTAT3, which
is the main downstream target of IL-6, was reduced in some
KrasG12D; IL-6-/- tumors (Figure 5) but increased in p53-deleted
tumors. These data indicated that IL-6 deletion altered tumor
expression of some inflammatory cytokines, although these
changes were weakened by p53 deletion.
Discussion
Previous studies have shown that carcinogen-induced
tumorigenesis in IL-6−/− mice is delayed by 1-2 weeks [4,47];
however, we found no difference in KrasG12D-induced tumor
onset regardless of IL-6 deficiency. One possible explanation is
that KrasG12D activation may induce lung tumorigenesis more
robustly than other carcinogens.
Some inflammatory cytokines are associated with tumor
progression [42]. TNFα may act as a tumor promoter by
regulating a cascade of cytokines, chemokines, adhesions,
matrix metalloproteinases (MMPs) and pro-angiogenic
activities [2,48]. In this study, IL-6 deletion in KrasG12D tumors
upregulated TNFα expression. Elevated expression of TNFα
may compensate for the loss of IL-6 and thus increase
tumorigenesis. However, tumor progression is delayed in
KrasG12D; IL-6-/- mice, consistent with previous results [4,47].
These data indicate that IL-6 is important for tumor progression
in vivo and suggest that IL-6 inhibition may have biphasic
stage-specific effects in lung cancer, enhancing tumorigenesis
early while suppressing tumor progression later. Consequently,
Figure 2.  IL-6 deletion attenuates proliferation but not apoptosis of tumor cells.  (A and B) Representative images of BrdU-
stained lung tissue sections from (A) K and (B) KI mice 20 weeks post-infection with adeno-Cre. (C) Quantification of BrdU-positive
tumor cells in lung tissue sections of K and KI mice (n=4) 20 weeks post-infection with adeno-Cre. *P<0.05. (D and E)
Representative images of pERK stained lung tissue sections from (D) K and (E) KI mice 20 weeks post-infection with adeno-Cre. (F
and G) Representative images of cleaved Caspase-3-stained lung tissue sections from (F) K and (G) KI mice 28 weeks post-
infection with adeno-Cre. Arrows indicate Caspase-3 positive tumor cells. Scale bar indicates 50 μm in (A, B, F and G), or 100 μm in
(D and E) . Abbreviations: K=KrasG12D. KI=KrasG12D; IL-6-/-.
doi: 10.1371/journal.pone.0080885.g002
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this may pose a risk to lung cancer patients treated with IL-6-
targeted therapy.
CCL-20 (or macrophage pro-inflammatory chemokine-3α,
MIP-3α), a C-C motif chemokine, is overexpressed in
pancreatic carcinoma cells and stimulates growth of tumor cells
[49]. CCL-19 (or macrophage inflammatory protein-3 beta,
MIP-3β), plays an important role in the migration of mature
dendritic cells and T-cells [50]. Both dendritic cells and T-cells
are double-edged swords in the tumor microenvironment, in
addition to initiating potent anti-tumor immune responses,
these cells may also stimulate cancerous cell growth and
spreading [51,52]. Persistently activated or tyrosine-
phosphorylated STAT3 (pSTAT3) is found in 50% of lung
adenocarcinomas [53,54]. pSTAT3 can enhance tumor
proliferation and loss of pSTAT3 arrests growth of premalignant
lesions, almost abrogating the development of advanced
tumors [55]. In this study, IL-6 deletion in KrasG12D tumors
resulted in downregulation of pSTAT3, CCL-19 and CCL-20.
pERK expression was reduced in KrasG12D; IL-6-/- tumors 20
weeks post-infection (Figure 2), but increased in most KrasG12D;
IL-6-/- tumors 32 weeks post-infection (Figure 5). These data
suggest that early stage, tumor growth may be delayed by low
expression of pERK, pSTAT3 and CCL-20. During later stages,
tumor growth may be induced by upregulation of pERK and
TNFα, although these mechanisms need further study.
Table 2. Site and frequency of metastases from primary
lung tumors.
Sites of metastases KrasG12D; p53flox/flox KrasG12D; p53flox/flox; IL-6-/-
Lymph node 10 of 19 (52.6%) 5 of 17 (29.4%)
Thymus 1 of 19 (5.3%) 1 of 17 (5.9%)
Heart 2 of 19 (10.5%) 0 of 17
doi: 10.1371/journal.pone.0080885.t002
Figure 3.  KP and KPI mice have high tumor burden, tumor cell proliferation and metastases.  Representative images of
lungs (A and B), BrdU staining (C and D), pERK staining (E and F) and tumor metastases (G and H) from KP (A, C, E, and G) and
KPI (B, D, F, and H) mice 12 weeks post-infection with adeno-Cre. Dotted lines (G and H) show metastastic tumor edges. Asterisks
indicate center of metastatic tumors. Scale bar indicates 500 μm (A, B, G, and H), 50 μm (C and D) or 100 μm (E and F).
Abbreviations: KP=KrasG12D; p53flox/flox. KPI=KrasG12D; p53flox/flox;IL-6-/-.
doi: 10.1371/journal.pone.0080885.g003
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Our data show that p53 deletion more dramatically affected
KrasG12D-induced lung cancer than IL-6 deletion. To a large
extent, p53 deletion attenuated the effects of IL-6 deletion on
delayed tumor growth and prolonged survival. p53 deletion
enhanced pSTAT3 expression (Figure 5) and abrogated the
change in CCL-20 expression in KrasG12D; p53flox/flox; IL-6-/-
tumors (Figure 4). p53 deletion also increased expression of
pAKT and total-AKT expression, which are associated with
high proliferation, in KrasG12D; p53flox/flox and KrasG12D; p53flox/flox;
IL-6-/- tumors(Figure 5). p53 deletion may attenuate the effects
of IL-6 deletion through these pathways.
We observed a trend for reduced metastases with IL-6
deletion (Table 2), although additional samples are required to
confirm this result. Separately, we have observed dramatically
increased IL-6 expression in primary and metastatic tumors
from mice with high metastatic rates (unpublished data), similar
to the report that IL-6 promotes cancer cells to metastasize to
distant sites [30,31]. Furthermore, survival time of KrasG12D;
p53flox/flox; IL-6-/- mice was significantly extended (P< 0.01)
(Table 1). These results indicate that IL-6 deletion may reduce
lung cancer metastases and prolong survival time in vivo
although p53 deletion dominantly impacts the evolution of
KrasG12D lung cancer.
The involvement of inflammation in tumorigenesis,
progression, and metastasis is widely accepted; however,
whether IL-6-targeted therapies will prolong the survival time of
lung cancer patients remains uncertain. Our results indicate
anti-IL-6 therapies may have some success in clinical trials. For
example, when NSCLC has not metastasized, IL-6 inhibition
may prolong survival but increase the risk of further
tumorigenesis; if metastasized, IL-6 inhibition may only
moderately impact metastasis but may lengthen survival time.
Further studies are needed to elucidate these possibilities. In
summary, our results provide evidence that IL-6 deficiency
promotes lung tumorigenesis, but suppresses tumor
progression and elongates survival in vivo. However, these
effects can be attenuated by p53 deletion.
Figure 4.  IL-6 deletion upregulates TNFα and downregulates CCL-19 and CCL-20 in tumors.  (A-D) Representative images of
MAC2-stained lung tissue sections from (A) K and (B) KI mice 28 weeks post-infection and from (C) KP and (D) KPI mice 12 weeks
post-infection with adeno-Cre. (E) Quantification of MAC2-positive macrophages in lung tumors from K, KI, KP, and KPI mice (n=3).
No statistical difference was observed. (F and G) Gene expression of IL-1β, TNFα, CCL-7, CCL-19, CCL-20, CXCL-5, CCL-8 and
CCL-24 in tumors from K, KI, KP, and KPI mice were determined by real-time PCR. Three to four tumors for each group were
detected and triplicate PCRs were performed. Gene expression was normalized to β-actin mRNA. * P<0.05 vs. K tumors.
Abbreviations: K=KrasG12D. KI=KrasG12D; IL-6-/-. KP=KrasG12D; p53flox/flox. KPI=KrasG12D; p53flox/flox;IL-6-/-.
doi: 10.1371/journal.pone.0080885.g004
p53 Loss Attenuates effects of IL-6 Inhibition
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e80885
Figure 5.  p53 deletion Increases pSTAT3 and pAKT expression in KrasG12D tumors.  Tumor lysates were extracted from K and
KI mice 32 weeks post-infection and from KP and KPI mice 15 weeks post-infection for Western blot analysis. Western blot results
of pSTAT3 and total-STAT3 were scanned by an ImageQuant LAS 4000mini (GE healthcare). Other results were exposed to X-ray
films. Abbreviations: K=KrasG12D. KI=KrasG12D; IL-6-/-. KP=KrasG12D; p53flox/flox. KPI=KrasG12D; p53flox/flox;IL-6-/-.
doi: 10.1371/journal.pone.0080885.g005
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Supporting Information
Figure S1.  PCR analysis of Kras allelic recombination. A
500 bp PCR product represents the floxed, unrecombined
KrasG12D allele; a 622 bp fragment represents the wildtype Kras
allele; and a 650 bp fragment represents a recombined
KrasG12D allele after removal of floxed stop cassette by adeno-
Cre. K, KI, KP, and KPI mice were treated with adeno-Cre and
the 650 bp recombined band revealed. Abbreviations: WT=
wildtype lungs. Floxed=floxed KrasG12D, without adeno-Cre
treatment. K=KrasG12D. KI=KrasG12D; IL-6-/-. KP=KrasG12D; p53flox/
flox. KPI=KrasG12D; p53flox/flox;IL-6-/-.
(TIF)
Figure S2.  IL-6 deletion attenuates tumor proliferation
determined by Ki67 staining. (A and B) Representative
images of Ki67-stained lung tissue sections from (A) K and (B)
KI mice 28 weeks post-infection with adeno-Cre. (C)
Quantification of Ki67-positive tumor cells in lung tissue
sections of K and KI mice (n=3). **P<0.01. Scale bar indicates
50 μm. Abbreviations: K=KrasG12D. KI=KrasG12D; IL-6-/-.
(TIF)
Figure S3.  PCR analysis of p53 allelic recombination. A
212 bp PCR product represents the floxed, unrecombined p53
allele; a 168 bp fragment represents the recombined allele after
inoculation with adeno-Cre; and a 130 bp fragment represents
the wildtype p53 allele. K, KI, KP, and KPI mice were treated
with adeno-Cre. The 168 bp recombined band was showed in
KP and KPI mice and 212 bp fragment remained due to tumor
stromal cells. Abbreviations: WT=wildtype lungs. Floxed=floxed
p53, without adeno-Cre treatment. K=KrasG12D. KI=KrasG12D;
IL-6-/-. KP=KrasG12D; p53flox/flox. KPI=KrasG12D; p53flox/flox;IL-6-/-.
(TIFF)
Figure S4.  KP and KPI mice develop metastatic lesions. (A
and B) Representative images of metastatic lesions to the (A)
pleura, (B) thymus in KPI mice 15 weeks post-infection with
adeno-Cre. Dotted lines in the images indicate metastatic
tumor edges. Asterisks indicate center of metastatic tumors.
(C) Representative image of heart metastases in KP mice 14
weeks post-infection with adeno-Cre. Metastatic lesions in the
heart are left of the dotted line. Scale bar indicates 200 μm (A)
or 100 μm (B and C). Abbreviations: KP=KrasG12D; p53flox/flox.
KPI=KrasG12D; p53flox/flox;IL-6-/-.
(TIF)
Figure S5.  Real-time PCR screen of changes in
inflammatory cytokines levels. .
Three tumors from each genotype were analyzed by real-time
PCR without replicate for expression of the indicated cytokine.
Gene expression was normalized to β-actin mRNA. *P<0.05
vs. K tumors. # P<0.05 vs. KP tumors. Abbreviations:
K=KrasG12D. KI=KrasG12D; IL-6-/-. KP=KrasG12D; p53flox/flox.
KPI=KrasG12D; p53flox/flox;IL-6-/-.
(TIF)
Figure S6.  Nuclear localization of p65 and β-catenin are
unchanged. Tumors from each mouse genotype were lysed to
obtain cytoplasmic (C) and nuclear (N) fractions. Lysates were
analyzed for the presence of nuclear p65 and β-catenin by
Western blot. Fraction purity was determined by GAPDH
(cytoplasmic) and PARP (nuclear) blots. Abbreviations:
K=KrasG12D. KI=KrasG12D; IL-6-/-. KP=KrasG12D; p53flox/flox.
KPI=KrasG12D; p53flox/flox;IL-6-/-.
(TIFF)
Table S1.  Primers for real-time PCR analysis of gene
expression.
(DOCX)
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